Clinical trials: Colon Cancer Stage III
Colorectal Neoplasms
Regorafenib in Subjects With Metastatic Colorectal Cancer (mCRC) Who Have Progressed After Standard Therapy
This is an open-label phase III study of regorafenib in patients with metastatic colorectal cancer (mCRC) who have progressed after all approved standard therapy.
- Trial name
- REGARD (NCT01853319)
- Testing
- Regorafenib (Stivarga, BAY73- 4506)
- Where
- 11 sites in Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Bayer